GlassScriptPhysician profile
Petek Donmez
NPI 1609953116
$6,533.19
in general payments reported to CMS, 2019-2025
38 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $685 · 2021: $1,293 · 2022: $1,130 · 2023: $1,030 · 2024: $834 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,334.98 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $640.57 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $503.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $379.87 | 2020-2025 | |
| Allergan, INC. | $361.02 | 2019-2020 | |
| Lilly USA, LLC | $213.27 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $206.77 | 2020-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.63 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $141.15 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $140.22 | 2022 | |
| Amgen INC. | $113.97 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $113.45 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.89 | 2020-2025 | Trintellix, Cuvitru |
| Horizon Therapeutics Plc | $79.14 | 2019-2021 | |
| Exact Sciences Corporation | $77.50 | 2023-2024 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Petek Donmez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.